reviewNature Reviews Drug DiscoveryJul 1, 2002Closed access

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

RCRenaud CapdevilleEBElisabeth BuchdungerJZJuerg ZimmermannAMAlex Matter

Novartis (Switzerland)

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,377
total citations
FWCI
23.37
Percentile
100%
References
77
Citations per year

Authors

4

Topics & keywords

Topics
Keywords
  • Medicine
  • Imatinib
  • Tolerability
  • Drug discovery
  • Drug
  • Anticancer drug
  • Imatinib mesylate
  • Modalities
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.